UNSPSC 51373301: Acetaminophen/dihydrocodeine/salicylamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51373301 Acetaminophen/dihydrocodeine/salicylamide is a Commodity code that in recent state and local practice covers pharmaceutical procurement across a broader range of OTC and generic drugs, not limited to the specific combination named in the code title. State and local buyers use this code to tag purchases of generic pharmaceuticals, naloxone, over-the-counter products, and branded or specialty drug sourcing through cooperative purchasing vehicles and direct procurement. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that serve participating state and local facilities. The scope of work ranges from community health initiatives requiring bulk naloxone and drug deactivation systems to statewide or multistate generic pharmaceutical contracting that aggregates demand across multiple jurisdictions and delivery locations.

Recent activity concentrates in Florida and Texas, with multistate cooperative purchasing spanning Minnesota and Oregon. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building; the Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026. The MMCAP procurement emphasizes pricing (75 percent evaluation weight), cGMP and Drug Supply Chain Security Act compliance, EDI capability, and maintenance of relationships with authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson.